NEW YORK (360Dx) – Qiagen said this week that it has joined Cancer-ID, a public-private consortium that aims to establish standard protocols and clinical validation for blood-based biomarkers in lung and breast cancer.

With 36 partners from 13 countries, the Cancer-ID consortium is a project of the Innovative Medicines Initiative, a European public-private program that aims to speed up the development of better and safer medicines for patients.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.